gutflix
GI learning, personalised

Summary

# A PREDICTIVE MODEL FOR HISTOLOGICAL RESPONSE TO THERAPY GUIDING THERAPEUTIC STRATEGIES IN ULCERATIVE COLITIS: A POST-HOC DATA ANALYSIS FROM A PHASE-II MIRIKIZUMAB CLINICAL TRIAL

Charles Owen

UEG Week Vienna 2024 Poster

IBD

October 13, 2024

**Post-hoc analysis of a phase II trial identifies faecal calprotectin, endoscopic remission, and Physician Global Assessment as predictors of histological remission in ulcerative colitis patients treated with mirikizumab.**

KEY POINTS

- In 106 patients receiving various doses of mirikizumab or placebo, histological remission (Geboes score <2) was achieved in 32.1% at week 12 and 39.6% at week 52.
- Faecal calprotectin <250 µg/g (OR 0.26, p<0.001), endoscopic remission (OR 0.16, p=.005), and less severe Physician Global Assessment significantly predicted histological remission in a generalized mixed model.
- Induction treatment with mirikizumab 200mg IV Q4W (OR 0.09, p=.004) or 600mg IV Q4W (OR 0.09, p=.006) and maintenance with 200mg SC Q4W (OR 0.05, p=.001) were associated with histological remission.
- The authors conclude the model may guide therapeutic strategy selection in clinical trials and practice, though validation in larger datasets is needed.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/73d566e4-9111-11ef-bdd5-0242ac140004

**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.